29 February 2024
29 February 2024
Palatin’s dry eye therapy PL9643 failed to meet endpoints in the Phase III trial without statistical adjustments.
Despite being one of the major causes of death globally, there are still plenty of unmet needs that need addressing.
The pharmacokinetic study will evaluate INBS’ drug screening solution in 40 healthy adults using fingerprint sweat analysis.
The US FDA granted fast-track designation for the IMPT-514 treatment in active and refractory LN and SLE.
Progression-free survival is the primary endpoint of the Phase II trial.
The Medidata platform streamlines study management from start to finish, eliminating the need for spreadsheets, data reconciliation.
Medivir said it has developed fostrox to be used as a combination therapy alongside Eisai’s Lenvima.
The alliance will focus on boosting participant enrolment in the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
